

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/004098

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.<sup>7</sup> A61K45/00, 31/7088, 31/7105, 39/395, 48/00, A61P35/00, 35/04, 43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.<sup>7</sup> A61K45/00, 31/7088, 31/7105, 39/395, 48/00, A61P35/00, 35/04, 43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho	1922-1996	Jitsuyo Shinan Toroku Koho	1996-2005
Kokai Jitsuyo Shinan Koho	1971-2005	Toroku Jitsuyo Shinan Koho	1994-2005

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
BIOSIS (STN), CAPLUS (STN), EMBASE (STN), MEDLINE (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A ✓	WO 2000/003728 A1 (SCHERING CORP.), 01 August, 2002 (01.08.02) & JP 2004-520043 A ✓ US 2002/0034494 A1 & EP 974357 A1	1-9, 14
A	JP 2003-530325 A (IPF PHARMACEUTICALS GMBH), 14 October, 2003 (14.10.03), & WO 2001/072830 A2 ✓ US 2003/0186889 A & EP 1268554 A2	1-9, 14
A	JP 2003-516324 A (SCHERING CORP.), 13 May, 2003 (13.05.03), ✓ WO 2001/038352 A2 & EP 1232185 A2	1-9, 14

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search  
31 May, 2005 (31.05.05)Date of mailing of the international search report  
14 June, 2005 (14.06.05)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/004098

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 2003-508388 A (CHEMOCENTRYX, INC.), 04 March, 2003 (04.03.03), & WO 2001/016114 A2 ✓ US 2003/0119854 A1 & EP 1216232 A2	1-9, 14
A	JP 2002-525338 A (Corixa Corp.), 13 August, 2002 (13.08.02), & US 2001/0006942 A1 ✓ US 2002/0039578 A1 & EP 1117429 A1 & WO 2000/018431 A1	1-9, 14
A ✓	JP 2002-513388 A (THEODOR-KOCHER INSTITUTE), 08 May, 2002 (08.05.02), ✓ WO 1998/011218 A1 ✓ US 6140064 A ✓ US 2003/158392 A1 & EP 925358 A1	1-9, 14
A	ROBLEDO M.M. et al., Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells., Journal of biological chemistry, 30 November, 2001 (30.11.01), 276(48), p.45098-105	1-9, 14
E, X ✓ E, Y	JP 2005-132761 A (Ono Pharmaceutical Co., Ltd.), 26 May, 2005 (26.05.05), (Family: none)	1-6, 8 7, 9

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/004098

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-13

because they relate to subject matter not required to be searched by this Authority, namely:

Claims 10 to 13 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.

2. ☐ Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## &lt;Subject of search&gt;

Claims 1, 5, 6 and 8 relate to medicinal compositions for treating cancer which contain, as the active ingredient(s), compounds defined by desired properties such as "a CXCR3 inhibitor", "a CXCR3-mediated signal transduction inhibitor in cancer cells", "a CXCR3 expression inhibitor", "a CXCR3 antagonist and an antibody against a CXCR3 ligand and a fragment thereof having an antigen-binding activity", "a CXCR3 antisense, siRNA and a CXCR3 expression inhibitor" and "a mutant of a CXCR3 ligand and a ligand-binding inhibitor". Although claims 1, 5, 6 and 8 involve any compounds having such properties, it is recognized that only small parts of the claimed compounds are supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

Even though the common technical knowledge at the point of the application is taken into consideration, the scope of the compounds having the property as "a CXCR3 inhibitor" cannot be specified. Thus, claims 1, 5, 6 and 8 do not comply with the requirement for clearness in the meaning within PCT Article 6 too.

Such being the case, the search was made on the relationship between the inhibition of CXCR3 and the treatment for cancer.